Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2004 | 12-2003 | 12-2002 | 12-2001 | 12-2000 | |
| Sales | 4,733 | 11,055 | 15,788 | 15,303 | 13,218 |
| Gross Profit | 4,733 | 11,055 | 15,788 | 15,303 | 13,218 |
| Operating Expenses | 61,600 | 51,882 | 52,804 | 40,263 | 38,723 |
| Operating Income | -56,867 | -40,827 | -37,016 | -24,960 | -25,505 |
| Interest Expense | 324 | 575 | 870 | 802 | 933 |
| Other Income | 936 | 205 | 856 | 1,957 | 1,078 |
| Pre-tax Income | -56,255 | -41,197 | -37,030 | -23,805 | -25,360 |
| Net Income Continuous | -56,255 | -41,197 | -37,030 | -23,805 | -25,360 |
| Net Income | $-56,255 | $-41,197 | $-37,030 | $-23,805 | $-25,360 |
| EPS Basic Total Ops | -31.20 | -36.20 | -74.10 | -57.50 | -440.14 |
| EPS Basic Continuous Ops | -31.16 | -36.15 | -74.13 | -57.46 | -314.28 |
| EPS Diluted Total Ops | -31.20 | -36.20 | -74.10 | -57.50 | -440.14 |
| EPS Diluted Continuous Ops | -31.16 | -36.15 | -74.13 | -57.46 | -314.28 |
| EBITDA(a) | $-54,494 | $-37,650 | $-31,192 | $-18,200 | $-17,948 |